Видео ютуба по тегу Fulvestrant

Fulvestrant in Breast Cancer
Fulvestrant in Breast Cancer
The significance of fulvestrant for hormone receptor-positive advanced breast cancer
The significance of fulvestrant for hormone receptor-positive advanced breast cancer
Dr. Goldstein on Fulvestrant in Metastatic Breast Cancer
Dr. Goldstein on Fulvestrant in Metastatic Breast Cancer
Palbociclib Combined With Fulvestrant in Relapsed Metastatic HR+/HER2- Breast Cancer
Palbociclib Combined With Fulvestrant in Relapsed Metastatic HR+/HER2- Breast Cancer
Dr. Verma on Palbociclib Plus Fulvestrant for HR+/HER2- Breast Cancer
Dr. Verma on Palbociclib Plus Fulvestrant for HR+/HER2- Breast Cancer
Role of Fulvestrant Monotherapy in HR+ mBC
Role of Fulvestrant Monotherapy in HR+ mBC
ALTERNATE: fulvestrant and/or anastrozole in ER+ HER2- postmenopausal breast cancer
ALTERNATE: fulvestrant and/or anastrozole in ER+ HER2- postmenopausal breast cancer
Estrogen receptor antagonists - Fulvestrant
Estrogen receptor antagonists - Fulvestrant
The Estrogen-Receptor Antagonist Fulvestrant in Breast Cancer
The Estrogen-Receptor Antagonist Fulvestrant in Breast Cancer
Dr. Adelson on Bortezomib plus Fulvestrant for HR+ Breast Cancer
Dr. Adelson on Bortezomib plus Fulvestrant for HR+ Breast Cancer
MONALEESA-3: Ribociclib Plus Fulvestrant in HR+ mBC
MONALEESA-3: Ribociclib Plus Fulvestrant in HR+ mBC
ESMO 2020 Highlights on alpelisib plus fulvestrant for HR+/HER2– ABC: The SOLAR-1 study
ESMO 2020 Highlights on alpelisib plus fulvestrant for HR+/HER2– ABC: The SOLAR-1 study
The Role of Fulvestrant in HR+ Breast Cancer
The Role of Fulvestrant in HR+ Breast Cancer
Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial
Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial
Abemaciclib + Fulvestrant at Progression of HR+ mBC
Abemaciclib + Fulvestrant at Progression of HR+ mBC
Is There Still a Role for Fulvestrant Hormone Monotherapy?
Is There Still a Role for Fulvestrant Hormone Monotherapy?
Fulvestrant in the Era of CDK4/6 Inhibitors for HR+ mBC
Fulvestrant in the Era of CDK4/6 Inhibitors for HR+ mBC
Second-line fulvestrant in pretreated metastatic invasive lobular carcinoma
Second-line fulvestrant in pretreated metastatic invasive lobular carcinoma
CAPItello-292: capivasertib, palbociclib, and fulvestrant for HR+ endocrine-resistant breast cancer
CAPItello-292: capivasertib, palbociclib, and fulvestrant for HR+ endocrine-resistant breast cancer